Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

-person">Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris added, "With more than $40 million in cash, including proceeds from our recent $15 million registered direct offering and no debt, combined with our expected significantly reduced burn rate, we are in a solid financial position to execute our focused drug development and business strategy."

CONSOLIDATED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2010

Revenues were $6.4 million for the three-month period ended March 31, 2010, compared to $6.1 million for the same period in 2009. The increase is mainly due to a comparative increase in sales of Cetrotide(R) to certain customers in the first quarter of 2010. This increase was partly offset by lower amortization of upfront license fee payments in 2010 related to our agreement with sanofi-aventis U.S. LLC ("sanofi-aventis"), which was entered into in March 2009, in connection with our now discontinued development program involving cetrorelix for the treatment of Benign Prostatic Hyperplasia ("BPH"), and subsequently terminated.

Research and development ("R&D") costs, net of tax credits and grants, were $5.7 million for the three-month period ended March 31, 2010, compared to $11.4 million for the same period in 2009. The comparative decrease in net R&D costs is almost entirely attributable to the winding down and termination of development activities related to cetrorelix in BPH, despite the presence in the first quarter of 2010 of residual expenditures associated with certain remaining contractual obligations.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... Texas Governor Rick Perry, Texas ... Health Science Center CEO Brett Giroir, M.D., and ... Human Services (HHS), State of Texas and biopharmaceutical ... vaccine manufacturing facility in Bryan, Texas, which when ... Texas A&M Biocorridor – a rapidly evolving hub ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts ... The global companion diagnostics market is expected to ... 2019. Factors such as rising need for personalized medicine ... the pharmaceutical industry, support from regulatory authorities, and emerging ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Inc., a clinical,stage biopharmaceutical company developing novel multi-component ... present at the,Wachovia 2008 Healthcare Conference in Boston, ... Among the topics of the presentation will ... developments, including Phase III development,activities related to its ...
... Jan. 28 Campbell Alliance, the leading,management consulting ... announced that Nader Naeymi-Rad, Senior,Vice President of the ... Oncology Summit Europe. The event will be held ... Hotel in London, England., Mr. Naeymi-Rad,s presentation, ...
... 28 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT.OB), ... disease, today announced the,appointment of Gregory W. Schafer ... the audit committee. Mr. Schafer is a seasoned ... biotechnology finance and operations., "We are delighted ...
Cached Biology Technology:Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit 2Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 2Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 3
(Date:9/19/2014)... The sense of fairness did not evolve for the ... reap the benefits of continued cooperation, so say Frans ... a review article about inequity aversion (IA), which is ... review is published in Science . , ... 35 IA-related studies to address their hypothesis that it ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... There are few things more irritating than a fly ... to the problem. They hang up a bunch of Roridula ... leaf,s hairs, the hapless pest is soon trapped by the ... story. Each R. gorgonias plant is home to a population ...
... model for studying the genetics of Angelman syndrome, a ... in one out of 15,000 births, has been developed ... Their research demonstrates that when a particular fruit ... behavioral dysfunctions similar to those experienced by humans whose ...
... Say the word "biofuels" and most people think of ... technology called gasification that,s getting a new look from ... and Iowa State University. By combining gasification with ... from a wide range of biomass, including distiller,s grain ...
Cached Biology News:Nothing stops an expert in the art of living 2Model for angelman syndrome developed by University of Texas at Austin biologists 2Turning waste material into ethanol 2
... LTQ XL extends the MSn performance of ... new tools to generate extensive structural information ... applications. , Multiple dissociation techniques (PQD, ... and unpredicted metabolites , Fast polarity switching ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
A substrate for all AChE-based EIA kits....
... secretion of cytoplasmic granules, is a ... of leukocytes (e.g. basophils, neutrophils, eosinophils, ... histamine, these secretory granules contain many ... and many proteases (Hallgren, 2001). Tryptase, ...
Biology Products: